Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 1
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean van thillo e[au] (9 results)?
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
Vanassche T, Engelen MM, Van Thillo Q, Wauters J, Gunst J, Wouters C, Vandenbriele C, Rex S, Liesenborghs L, Wilmer A, Meersseman P, Van den Berghe G, Dauwe D, Verbeke G, Thomeer M, Fivez T, Mesotten D, Ruttens D, Heytens L, Dapper I, Tuyls S, De Tavernier B, Verhamme P; DAWn consortium members. Vanassche T, et al. Among authors: van thillo q. Trials. 2020 Dec 9;21(1):1005. doi: 10.1186/s13063-020-04878-y. Trials. 2020. PMID: 33298149 Free PMC article. Clinical Trial.
Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia.
Van Thillo Q, De Bie J, Seneviratne JA, Demeyer S, Omari S, Balachandran A, Zhai V, Tam WL, Sweron B, Geerdens E, Gielen O, Provost S, Segers H, Boeckx N, Marshall GM, Cheung BB, Isobe K, Kato I, Takita J, Amos TG, Deveson IW, McCalmont H, Lock RB, Oxley EP, Garwood MM, Dickins RA, Uyttebroeck A, Carter DR, Cools J, de Bock CE. Van Thillo Q, et al. Nat Commun. 2021 Jul 6;12(1):4164. doi: 10.1038/s41467-021-24442-9. Nat Commun. 2021. PMID: 34230493 Free PMC article.
Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
Vanassche T, Engelen MM, Van Thillo Q, Wauters J, Gunst J, Wouters C, Vandenbriele C, Rex S, Liesenborghs L, Wilmer A, Meersseman P, Van den Berghe G, Dauwe D, Verbeke G, Thomeer M, Fivez T, Mesotten D, Ruttens D, Heytens L, Dapper I, Tuyls S, De Tavernier B, Verhamme P; DAWn consortium members. Vanassche T, et al. Among authors: van thillo q. Trials. 2020 Dec 29;21(1):1033. doi: 10.1186/s13063-020-04991-y. Trials. 2020. PMID: 33375932 Free PMC article. No abstract available.
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
Devos T, Van Thillo Q, Compernolle V, Najdovski T, Romano M, Dauby N, Jadot L, Leys M, Maillart E, Loof S, Seyler L, Moonen M, Moutschen M, Van Regenmortel N, Ariën KK, Barbezange C, Betrains A, Garigliany M, Engelen MM, Gyselinck I, Maes P, Schauwvlieghe A, Liesenborghs L, Belmans A, Verhamme P, Meyfroidt G; DAWn-plasma investigators. Devos T, et al. Among authors: van thillo q. Eur Respir J. 2022 Feb 10;59(2):2101724. doi: 10.1183/13993003.01724-2021. Print 2022 Feb. Eur Respir J. 2022. PMID: 34446469 Free PMC article. Clinical Trial.
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO).
Gyselinck I, Liesenborghs L, Belmans A, Engelen MM, Betrains A, Van Thillo Q, Nguyen PAH, Goeminne P, Soenen AC, De Maeyer N, Pilette C, Papleux E, Vanderhelst E, Derweduwen A, Alexander P, Bouckaert B, Martinot JB, Decoster L, Vandeurzen K, Schildermans R, Verhamme P, Janssens W, Vos R. Gyselinck I, et al. Among authors: van thillo q. ERJ Open Res. 2022 Feb 28;8(1):00610-2021. doi: 10.1183/23120541.00610-2021. eCollection 2022 Jan. ERJ Open Res. 2022. PMID: 35233389 Free PMC article.